Form 4: Merck Executive Dalton Smart Reports Stock Transactions
SEC Form 4 Filing
Dalton Smart, SVP Fin. Global Controller at Merck & Co., Inc., reported the acquisition and disposal of common stock and derivative securities.
Summary
- Dalton Smart, a senior executive at Merck & Co., Inc., filed a Form 4 detailing changes in beneficial ownership of the company's securities.
- On May 2, 2024, Smart exercised stock options to acquire 381 shares of common stock at $128.8 per share.
- Also on May 2, 2024, Smart disposed of 131 shares to cover tax obligations at $128.8 per share.
- As of May 2, 2024, Smart directly owns 2,917.286 shares of Merck common stock.
- On April 30, 2024, Smart was granted 1,393 restricted stock units (RSUs) that vest in three equal installments starting April 30, 2025.
- On April 30, 2024, Smart was granted options to purchase 7,031 shares of common stock that vest in three equal installments starting April 30, 2025.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects routine transactions and grants of equity compensation.
Positives
- The granting of RSUs and stock options to a senior executive suggests the company's confidence in its future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Stock option and RSU grants are a common form of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders.
- Companies like Pfizer (PFE) and Johnson & Johnson (JNJ) also utilize similar equity-based compensation plans for their executives.
- The vesting schedules and grant sizes are generally comparable to industry norms for executives at similar levels.
Stakeholder Impact
- The transactions reported in the Form 4 provide transparency to shareholders regarding the trading activities of a key executive.
- The equity-based compensation plans aim to align the interests of management with those of shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 04/30/2024 | Date of grant of restricted stock units and stock options. |
| 04/30/2025 | First vesting date for restricted stock units and stock options granted on 04/30/2024. |
| 04/30/2026 | Second vesting date for restricted stock units and stock options granted on 04/30/2024. |
| 04/30/2027 | Third vesting date for restricted stock units and stock options granted on 04/30/2024. |
| 05/02/2024 | Date of stock option exercise and share disposal. |
| 05/02/2024 | First vesting date for restricted stock units granted on 05/02/2024. |
| 05/02/2025 | Second vesting date for restricted stock units granted on 05/02/2024. |
| 05/02/2026 | Third vesting date for restricted stock units granted on 05/02/2024. |
| 04/29/2034 | Expiration date for stock options granted on 04/30/2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.